Evidence map›Paper›PMID 17372005›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2007

The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates LIR-1- NK cells.

Virginie Prod'homme, Cora Griffin, Rebecca J Aicheler, Eddie C Y Wang, Brian P McSharry, Carole R Rickards, Richard J Stanton, Leszek K Borysiewicz, Miguel López-Botet, Gavin W G Wilkinson and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 139 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. HCMV-secreted glycoprotein gpUL4 inhibits TRAIL-mediated apoptosis and NK cell activation.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  15. ADAM17 targeting by human cytomegalovirus remodels the cell surface proteome to simultaneously regulate multiple immune pathways.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  16. Review
  17. Review
  18. Review
  19. Variants of HCMVInternational journal of molecular sciences · 2022
    Article
  20. Review

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Virginie Prod'hommeDepartment of Medical Microbiology, Cardiff University, Heath Park, Cardiff, Wales, UK.
Cora Griffin
Rebecca J Aicheler
Eddie C Y Wang
Brian P McSharry
Carole R Rickards
Richard J Stanton
Leszek K Borysiewicz
Miguel López-Botet
Gavin W G Wilkinson
Peter Tomasec
Cardiff University · GBCzech Academy of Sciences, Institute of Microbiology · CZImperial College London · GBPompeu Fabra University · ES

Funding

Medical Research Council G0300180Medical Research Council G0300180(65735)Medical Research Council G0500617Medical Research Council G0500617(74644)Medical Research Council G0700142Wellcome Trust
6 · The paper itself

Abstract

The inhibitory leukocyte Ig-like receptor 1 (LIR-1, also known as ILT2, CD85j, or LILRB1) was identified by its high affinity for the human CMV (HCMV) MHC class I homolog gpUL18. The role of this LIR-1-gpUL18 interaction in modulating NK recognition during HCMV infection has previously not been clearly defined. In this study, LIR-1(+) NKL cell-mediated cytotoxicity was shown to be inhibited by transduction of targets with a replication-deficient adenovirus vector encoding UL18 (RAd-UL18). Fibroblasts infected with an HCMV UL18 mutant (DeltaUL18) also exhibited enhanced susceptibility to NKL killing relative to cells infected with the parental virus. In additional cytolysis assays, UL18-mediated protection was also evident in the context of adenovirus vector transduction and HCMV infection of autologous fibroblast targets using IFN-alpha-activated NK bulk cultures derived from a donor with a high frequency of LIR-1(+) NK cells. A single LIR-1(high) NK clone derived from this donor was inhibited by UL18, while 3 of 24 clones were activated. CD107 mobilization assays revealed that LIR-1(+) NK cells were consistently inhibited by UL18 in all tested donors, but this effect was often masked in the global response by UL18-mediated activation of a subset of LIR-1(-) NK cells. Although Ab-blocking experiments support UL18 inhibition being induced by a direct interaction with LIR-1, the UL18-mediated activation is LIR-1 independent.

Indexed as

AdenoviridaeAntigens, CDCapsid ProteinsCells, CulturedCytotoxicity, ImmunologicGenetic VectorsHistocompatibility Antigens Class IHumansKiller Cells, NaturalLeukocyte Immunoglobulin-like Receptor B1Lymphocyte ActivationReceptors, ImmunologicSequence DeletionAntigens, CDCapsid ProteinsHistocompatibility Antigens Class ILeukocyte Immunoglobulin-like Receptor B1LILRB1 protein, humanReceptors, ImmunologicVP23 protein, Human herpesvirus 1

Identifiers

PMID17372005
PMCPMC2843079
OpenAlexW2146701364

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.